( MENAFN - 3BL) ABBOTT PARK, Ill., June 10, 2024 /3BL/ - Abbott (NYSE: ABT) today announced U.S.
Food and Drug Administration (FDA) clearance for two new over-the-counter continuous glucose monitoring (CGM) systems – LingoTM and Libre RioTM, which are based on Abbott's world-leading FreeStyle Libre® continuous glucose monitoring technology1, now used by about 6 million people globally2. The newly cleared systems have been intentionally designed to meet different needs – Lingo for consumers who want to better understand and improve their health and wellness, and Libre Rio for adults with Type 2 diabetes who do not use insulin and typically manage their diabetes through lifestyle modifications. "There is no one-size-fits all approach for glucose monitoring, which is why we've designed different products for different people – all based on the same world-leading biowearable technology1," said Lisa Earnhardt, executive vice president and group president of Abbott's medical devices business.
"People living with diabetes need certain features like tracking medications or sharing data with a healthcare provider. People without diabetes need different features to manage their metabolic health, including personalized coaching to promote actionable lifestyle changes." Lingo Abbott's consumer biowearable, Lingo, is designed for consumers 18 years and older who are looking to improve their overall health and wellness.
Lingo will track glucose and provide personalized insights and .